proline and gefitinib

proline has been researched along with gefitinib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
DU, JX; Gong, WX; Huang, SC; Liang, CW; Pan, Y; Peng, DX; Quan, W; Wang, X; Xie, Y; Zhang, N; Zheng, LP1
Liang, L; Wang, X; Yin, W1

Other Studies

2 other study(ies) available for proline and gefitinib

ArticleYear
[Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2018, May-20, Volume: 38, Issue:5

    Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; NF-kappa B p50 Subunit; Proline; Thiocarbamates; Transcription Factor RelA

2018
PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug.
    Pathology, research and practice, 2022, Volume: 237

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Co-Repressor Proteins; CTLA-4 Antigen; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glutamates; Humans; Leucine; Lung Neoplasms; Proline; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Transcription Factors

2022